Sarepta Therapeutics
SRPT
₹1,558
Share price
0.25%
Change (1 day)
-87.70%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) - Total debt
Total debt on the balance sheet as of March 2025 : ₹114.74 Billion
According to Sarepta Therapeutics 's latest financial reports the company's total debt is ₹114.74 Billion. A company’s total debt is the sum of all current and non-current debts.
Sarepta Therapeutics - Total debt on balance sheet (from 2007 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | ₹115.21 B | -0.92% |
| 2023-12-31 | ₹116.28 B | -13.12% |
| 2022-12-31 | ₹133.83 B | 55.89% |
| 2021-12-31 | ₹85.85 B | 9.42% |
| 2020-12-31 | ₹78.46 B | 50.8% |
| 2019-12-31 | ₹52.02 B | 76.94% |
| 2018-12-31 | ₹29.40 B | 6.84% |
| 2017-12-31 | ₹27.52 B | 2407.85% |
| 2016-12-31 | ₹1.09 B | -29.42% |
| 2015-12-31 | ₹1.55 B | 287.71% |
| 2014-12-31 | ₹0.40 B | 289.19% |
| 2013-12-31 | ₹0.10 B | 7.12% |
| 2012-12-31 | ₹96.2 M | -1.27% |
| 2011-12-31 | ₹97.44 M | 13.08% |
| 2010-12-31 | ₹86.16 M | -7.19% |
| 2009-12-31 | ₹92.84 M | -25.42% |
| 2008-12-31 | ₹0.12 B | 48.1% |
| 2007-12-31 | ₹84.05 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | ₹2.130 T | 1,756.89% | 🇺🇸 USA |
 Novavax NVAX | ₹19.52 B | -82.98% | 🇺🇸 USA |
 Avidity Biosciences RNA | ₹0.51 B | -99.56% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | ₹67.88 B | -40.84% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | ₹111.14 B | -3.13% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | ₹33.26 B | -71.01% | 🇺🇸 USA |
 Insmed INSM | ₹97.63 B | -14.91% | 🇺🇸 USA |